Misplaced Pages

Minamestane

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Minamestane
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • 4-aminoandrosta-1,4,6-triene-3,17-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H23NO2
Molar mass297.398 g·mol
3D model (JSmol)
SMILES
  • O=C4\C=C/3(C(/C=C\21(C(=O)CC1)(CC23)C)=C4/N)C
InChI
  • InChI=1S/C19H23NO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h3-4,8,10-13H,5-7,9,20H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
  • Key:DAKHYLIFCYPHQW-KZQROQTASA-N

Minamestane (INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by Farmitalia-Carlo Erba as an antineoplastic agent in the mid-1990s but was never marketed.

Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties.

See also

References

  1. F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1357. ISBN 978-0-412-46630-4. Retrieved 20 May 2012.
  2. ^ Di Salle E, Briatico G, Giudici D, et al. (June 1994). "Novel aromatase and 5 alpha-reductase inhibitors". The Journal of Steroid Biochemistry and Molecular Biology. 49 (4–6): 289–94. doi:10.1016/0960-0760(94)90270-4. PMID 8043491. S2CID 54350143.
  3. Combs, Donald W (1995). "Review Oncologic, Endocrine & Metabolic: Recent developments in aromatase inhibitors". Expert Opinion on Therapeutic Patents. 5 (6): 529533. doi:10.1517/13543776.5.6.529. ISSN 1354-3776.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Minamestane Add topic